{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:40Z","timestamp":1792839700085,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K08338"],"award-info":[{"award-number":["JP20K08338"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22fk0210113"],"award-info":[{"award-number":["JP22fk0210113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It is unclear whether hepatocyte function and\/or portal hypertension improves if a sustained virologic response (SVR) is achieved with direct-acting antivirals in patients with decompensated hepatitis C-related cirrhosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We examined the safety and efficacy of a 12-week course of sofosbuvir\/velpatasvir (SOF\/VEL) in 20 patients with decompensated hepatitis C-related cirrhosis. We also investigated changes in the hepatocyte receptor index (LHL15) and blood clearance index (HH15) by Tc-99\u00a0m-galactosyl human serum albumin scintigraphy, liver stiffness measurement (LSM) by transient elastography, and hepatic venous pressure gradient (HVPG) in patients who achieved an SVR at 24\u00a0weeks after treatment (SVR24).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One patient discontinued treatment because of rectal variceal hemorrhage, and 19 patients completed treatment. SVR24 was achieved in 17 patients (89%). Median LHL15 increased from 0.72 pre-treatment to 0.82 after SVR24 (<jats:italic>p<\/jats:italic>\u2009=\u20090.012), and median HH15 decreased from 0.82 pre-treatment to 0.76 after SVR24 (<jats:italic>p<\/jats:italic>\u2009=\u20090.010). The percentage of patients with LSM\u2009\u2265\u200920\u00a0kPa was 90% before treatment and remained at 90% after SVR24. However, the percentage with severe portal hypertension (defined as HVPG\u2009\u2265\u200912\u00a0mmHg) decreased from 92% pre-treatment to 58% after SVR24 (<jats:italic>p<\/jats:italic>\u2009=\u20090.046). Patients with a decreased HVPG from pre-treatment to after SVR24 had a smaller pre-treatment spleen volume than those with an increased HVPG (median, 252 vs. 537\u00a0mL, <jats:italic>p<\/jats:italic>\u2009=\u20090.028).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Achieving SVR24 with SOF\/VEL treatment in patients with decompensated hepatitis C-related cirrhosis can be expected to improve hepatocyte function and portal hypertension on short-term follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00535-023-01963-2","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T12:07:01Z","timestamp":1675339621000},"page":"394-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir\/velpatasvir for decompensated hepatitis C-related cirrhosis"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4035-4984","authenticated-orcid":false,"given":"Kohei","family":"Kotani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Uchida-Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Yukawa-Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Odagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Motoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuzo","family":"Kozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsushi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Higashiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"1963_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jgh.15703","volume":"37","author":"E Ogawa","year":"2022","unstructured":"Ogawa E, Kawano A, Ooho A, et al. Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection. J Gastroenterol Hepatol. 2022;37:371\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"1963_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","volume":"152","author":"P Nahon","year":"2017","unstructured":"Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152:142-56.e2.","journal-title":"Gastroenterology"},{"key":"1963_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jvh.13232","volume":"27","author":"SA McDonald","year":"2020","unstructured":"McDonald SA, Pollock KG, Barclay ST, et al. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. J Viral Hepat. 2020;27:270\u201380.","journal-title":"J Viral Hepat"},{"key":"1963_CR4","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","volume":"74","author":"LAP Krassenburg","year":"2021","unstructured":"Krassenburg LAP, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021;74:1053\u201363.","journal-title":"J Hepatol"},{"key":"1963_CR5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1365-2036.2008.03620.x","volume":"27","author":"GT Everson","year":"2008","unstructured":"Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. 2008;27:542\u201351.","journal-title":"Aliment Pharmacol Ther"},{"key":"1963_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/apt.13844","volume":"45","author":"P Schwabl","year":"2017","unstructured":"Schwabl P, Mandorfer M, Steiner S, et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 2017;45:139\u201349.","journal-title":"Aliment Pharmacol Ther"},{"key":"1963_CR7","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1111\/j.1572-0241.2006.00743.x","volume":"101","author":"D Rincon","year":"2006","unstructured":"Rincon D, Ripoll C, Lo lacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol. 2006;101:2269\u201374.","journal-title":"Am J Gastroenterol"},{"key":"1963_CR8","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/hepr.13554","volume":"50","author":"Y Nagaoki","year":"2020","unstructured":"Nagaoki Y, Imamura M, Teraoka Y, et al. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res. 2020;50:1222\u201333.","journal-title":"Hepatol Res"},{"key":"1963_CR9","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. https:\/\/www.hcvguidelines.org. Accessed 29 Jul 2022"},{"key":"1963_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170\u2013218.","journal-title":"J Hepatol"},{"key":"1963_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/hepr.13503","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan society of hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020;50:791\u2013816.","journal-title":"Hepatol Res"},{"key":"1963_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","volume":"54","author":"T Takehara","year":"2019","unstructured":"Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87\u201395.","journal-title":"J Gastroenterol"},{"key":"1963_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00535-020-01733-4","volume":"56","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67\u201377.","journal-title":"J Gastroenterol"},{"key":"1963_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII\u2013renewing consensus in portal hypertension. J Hepatol. 2022;76:959\u201374.","journal-title":"J Hepatol"},{"key":"1963_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/jvh.12850","volume":"25","author":"R Kozuka","year":"2018","unstructured":"Kozuka R, Hai H, Motoyama H, et al. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-na\u00efve patients with chronic HCV genotype 1b infection in a real-world cohort. J Viral Hepat. 2018;25:535\u201342.","journal-title":"J Viral Hepat"},{"key":"1963_CR16","first-page":"1652","volume":"40","author":"N Sasaki","year":"1999","unstructured":"Sasaki N, Shiomi S, Iwata Y, et al. Clinical usefulness of scintigraphy with 99mTc-galactosyl-human serum albumin for prognosis of cirrhosis of the liver. J Nucl Med. 1999;40:1652\u20136.","journal-title":"J Nucl Med"},{"key":"1963_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011765","volume":"97","author":"K Kotani","year":"2018","unstructured":"Kotani K, Kawabe J, Higashiyama S, et al. Heterogeneous liver uptake of Tc-99m-GSA as quantified through SPECT\/CT helps to evaluate the degree of liver fibrosis: a retrospective observational study. Medicine (Baltimore). 2018;97: e11765.","journal-title":"Medicine (Baltimore)"},{"key":"1963_CR18","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/gutjnl-2020-322367","volume":"70","author":"A Yamamoto","year":"2021","unstructured":"Yamamoto A, Kawada N, Jogo A, et al. Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein. Gut. 2021;70:1199\u2013201.","journal-title":"Gut"},{"key":"1963_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis R, Faculty BVI. Expanding consensus in portal hypertension: report of the baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743\u201352.","journal-title":"J Hepatol"},{"key":"1963_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the liver","year":"2018","unstructured":"European Association for the Study of the liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406\u201360.","journal-title":"J Hepatol"},{"key":"1963_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/hepr.13739","volume":"52","author":"M Atsukawa","year":"2022","unstructured":"Atsukawa M, Tsubota A, Kondo C, et al. Time-course changes in liver functional reserve after successful sofosbuvir\/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res. 2022;52:235\u201346.","journal-title":"Hepatol Res"},{"key":"1963_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00535-021-01845-5","volume":"57","author":"Y Tahata","year":"2022","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022;57:120\u201332.","journal-title":"J Gastroenterol"},{"key":"1963_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13837.(inpress)","author":"T Sano","year":"2022","unstructured":"Sano T, Amano K, Ide T, et al. A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir\/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res. 2022. https:\/\/doi.org\/10.1111\/hepr.13837.(inpress).","journal-title":"Hepatol Res"},{"key":"1963_CR24","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1093\/cid\/ciaa502","volume":"71","author":"C Diez","year":"2020","unstructured":"Diez C, Berenguer J, Ibanez-Samaniego L, et al. Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis. Clin Infect Dis. 2020;71:2726\u20139.","journal-title":"Clin Infect Dis"},{"key":"1963_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/jvh.12706","volume":"24","author":"N Afdhal","year":"2017","unstructured":"Afdhal N, Everson GT, Calleja JL, et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017;24:823\u201331.","journal-title":"J Viral Hepat"},{"key":"1963_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","volume":"65","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692\u20139.","journal-title":"J Hepatol"},{"key":"1963_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","volume":"153","author":"S Lens","year":"2017","unstructured":"Lens S, Alvarado-Tapias E, Mari\u00f1o Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. 2017;153:1273-83.e1.","journal-title":"Gastroenterology"},{"key":"1963_CR28","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","volume":"73","author":"S Lens","year":"2020","unstructured":"Lens S, Baiges A, Alvarado-Tapias E, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol. 2020;73:1415\u201324.","journal-title":"J Hepatol"},{"key":"1963_CR29","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618\u201328.","journal-title":"N Engl J Med"},{"key":"1963_CR30","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1002\/jmv.27157","volume":"93","author":"T Tada","year":"2021","unstructured":"Tada T, Kurosaki M, Nakamura S, et al. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol. 2021;93:6247\u201356.","journal-title":"J Med Virol"},{"key":"1963_CR31","first-page":"125","volume":"17","author":"T Kira","year":"1999","unstructured":"Kira T, Tomiguchi S, Takahashi M, et al. Correlation of 99mTc-GSA hepatic scintigraphy with liver biopsies in patients with chronic active hepatitis type C. Radiat Med. 1999;17:125\u201330.","journal-title":"Radiat Med"},{"key":"1963_CR32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s12149-011-0484-0","volume":"25","author":"R Ishii","year":"2011","unstructured":"Ishii R, Togashi H, Iwaba A, et al. (99m)Tc-GSA SPECT analysis was clinically useful to evaluate the effect of interferon in a patient with interferon non-responsive chronic hepatitis C. Ann Nucl Med. 2011;25:520\u20133.","journal-title":"Ann Nucl Med"},{"key":"1963_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1152\/physrev.1995.75.3.591","volume":"75","author":"RJ Stockert","year":"1995","unstructured":"Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev. 1995;75:591\u2013609.","journal-title":"Physiol Rev"},{"key":"1963_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.autrev.2012.04.005","volume":"12","author":"EI Rigopoulou","year":"2012","unstructured":"Rigopoulou EI, Roggenbuck D, Smyk DS, et al. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun Rev. 2012;12:260\u20139.","journal-title":"Autoimmun Rev"},{"key":"1963_CR35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jcp.1041580319","volume":"158","author":"U Treichel","year":"1994","unstructured":"Treichel U, Paietta E, Poralla T, et al. Effects of cytokines on synthesis and function of the hepatic asialoglycoprotein receptor. J Cell Physiol. 1994;158:527\u201334.","journal-title":"J Cell Physiol"},{"key":"1963_CR36","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/hep.1840150425","volume":"15","author":"JB Burgess","year":"1992","unstructured":"Burgess JB, Baenziger JU, Brown WR. Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis. Hepatology. 1992;15:702\u20136.","journal-title":"Hepatology"},{"key":"1963_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/hepr.12621","volume":"46","author":"E Miyaki","year":"2016","unstructured":"Miyaki E, Imamura M, Hiraga N, et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2016;46:758\u201364.","journal-title":"Hepatol Res"},{"key":"1963_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.aohep.2020.04.002","volume":"19","author":"K Kikukawa","year":"2020","unstructured":"Kikukawa K, Uchida-Kobayashi S, Tamori A, et al. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients. Ann Hepatol. 2020;19:367\u201372.","journal-title":"Ann Hepatol"},{"key":"1963_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2: 100067.","journal-title":"JHEP Rep"},{"key":"1963_CR40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10238-021-00749-1","volume":"22","author":"WF Barbosa","year":"2022","unstructured":"Barbosa WF, Andrade VG, Braz AMM, et al. Cirrhosis regression after SVR with indirect methods of fibrosis analysis: how far is it real? Clin Exp Med. 2022;22:269\u201375.","journal-title":"Clin Exp Med"},{"key":"1963_CR41","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s00535-017-1345-y","volume":"52","author":"K Morio","year":"2017","unstructured":"Morio K, Imamura M, Daijo K, et al. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. J Gastroenterol. 2017;52:1252\u20137.","journal-title":"J Gastroenterol"},{"key":"1963_CR42","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/jvh.13261","volume":"27","author":"F Poordad","year":"2020","unstructured":"Poordad F, Castro RE, Asatryan A, et al. Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir\/paritaprevir\/ritonavir + dasabuvir \u00b1 ribavirin in the TOPAZ-I and TOPAZ-II trials. J Viral Hepat. 2020;27:497\u2013504.","journal-title":"J Viral Hepat"},{"key":"1963_CR43","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1177\/2050640618791053","volume":"6","author":"M Enomoto","year":"2018","unstructured":"Enomoto M, Ikura Y, Tamori A, et al. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. United Eur Gastroenterol J. 2018;6:1391\u2013400.","journal-title":"United Eur Gastroenterol J"},{"key":"1963_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310\u201335.","journal-title":"Hepatology"},{"key":"1963_CR45","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/jhep.2003.50133","volume":"37","author":"JG Abraldes","year":"2003","unstructured":"Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902\u20138.","journal-title":"Hepatology"},{"key":"1963_CR46","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/hep.31125","volume":"72","author":"V La Mura","year":"2020","unstructured":"La Mura V, Garcia-Guix M, Berzigotti A, et al. A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding. Hepatology. 2020;72:1353\u201365.","journal-title":"Hepatology"},{"key":"1963_CR47","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","volume":"131","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611\u201324.","journal-title":"Gastroenterology"},{"key":"1963_CR48","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","volume":"62","author":"T Reiberger","year":"2013","unstructured":"Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634\u201341.","journal-title":"Gut"},{"key":"1963_CR49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/hepr.13471","volume":"50","author":"S Tsuji","year":"2020","unstructured":"Tsuji S, Uchida Y, Uemura H, et al. Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatol Res. 2020;50:512\u201323.","journal-title":"Hepatol Res"},{"key":"1963_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/hepr.13576","volume":"51","author":"Y Takaoka","year":"2021","unstructured":"Takaoka Y, Miura K, Morimoto N, et al. Real-world efficacy and safety of 12-week sofosbuvir\/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol Res. 2021;51:51\u201361.","journal-title":"Hepatol Res"},{"key":"1963_CR51","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S1590-8658(02)80246-8","volume":"34","author":"M Bolognesi","year":"2002","unstructured":"Bolognesi M, Merkel C, Sacerdoti D, et al. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis. 2002;34:144\u201350.","journal-title":"Dig Liver Dis"},{"key":"1963_CR52","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1053\/he.2000.6596","volume":"31","author":"N Nagasue","year":"2000","unstructured":"Nagasue N, Dhar DK, Yamanoi A, et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology. 2000;31:1107\u201314.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-01963-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-01963-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-01963-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T14:07:57Z","timestamp":1680012477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-01963-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1963"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-01963-2","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NK received lecture fees and research funding from Gilead Sciences, AbbVie, and MSD, and a scholarship donation from AbbVie. AT received research funding from Gilead Sciences. HF received research funding from MSD. SUK received research funding from Bristol-Myers and MSD, and scholarship donation from AbbVie. All other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}